PHASE 1 Complete

PHASE 2-4 Update

Clinical Reality & Target Matrix Alignment:

"While direct nucleic acid amplification (PCR/RPA) is highly effective for quantifying pathogen loads within vector specimens (ticks/insects), standard clinical human medicine demonstrates that bloodborne Borrelia burgdorferi rapidly leaves systemic circulation. Therefore, Project Bio-Surveillance separates its diagnostic pathways: employing direct molecular (DNA/RNA) amplification for vector and tissue analysis, while integrating protein-based immunoassay protocols (antigen/antibody detection) for human serological applications in future clinical expansion phases."

PROGRAM SUMMARY & AUTHORIZATION

Project Bio-Surveillance transitions vector diagnostics from a slow, retrospective reporting model into an active, real-time, predictive surveillance network. By grounding early-stage fluidics in proven human MEMS paradigms, the platform mitigates foundational hardware risks while establishing an immediate, data-rich ingestion layer through Phase 1 and Phase 2 deployments.

The Q2 2027 silicon launch of the monolithic Phase 3/4 non-Von Neumann architecture establishes an insurmountable technological moat—providing milliwatt-level, off-grid pathogen intelligence across vector-borne disease control, livestock biosecurity, wildlife management, and human point-of-care clinical diagnostics worldwide.